Beta Health Cancer Research Pharm is a wholly owned subsidiary of Beta Health Cancer Research Pharm, a global pharmaceutical company specialising in the manufacture and distribution of generic pharmaceutical medicines.
Beta Health Cancer Research Pharm is a rapidly growing pharmaceutical company with an increasingly strong market presence within the UK market, operating within retail pharmacy, wholesale and hospital sectors. Beta Health Cancer Research Pharm stands on the principles of providing high quality prescriptive medicines at an affordable price.
Our focus is to expand an ever-increasing product portfolio through group development of key pharmaceutical molecules and key partner arrangements, across a range of therapies with particular focus on the treatment areas affecting the cardiovascular and central nervous system.
The Company, internationally, is ranked amongst the leaders in the therapeutic segments of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective, pain management, gynecology and pediatric segments. Recently it has been expanding it's presence in the therapeutic segments of oncology and rheumatology.
Beta Health Cancer Research Pharm's competitive advantage stems from its world-class manufacturing facilities, advanced R&D capabilities, extensive domestic network and a widespread global presence in over 40 countries.